EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Gut Microbiota Predicts Treatment Response to Empagliflozin Among MASLD Patients Without Diabetes Mellitus

Ho Yu Ng, Lina Zhang, Jing Tong Tan, Rex Wan Hin Hui, Man Fung Yuen iD, Wai Kay Seto iD, Wai K Leung, Ka Shing Cheung iD

Liver International · 2025

DOI: 10.1111/liv.70023 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, 2025. Verfasst von Ho Yu Ng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Glucosides, Benzhydryl Compounds, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: General Research Fund, Research Grant Council, The Government of the Hong Kong Special Administrative Region.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim We aimed to investigate whether gut microbiota could predict the treatment response to pharmacological agents among metabolic dysfunction‐associated steatotic liver disease (MASLD) patients without diabetes mellitus (DM), as data are lacking.

Methods

We prospectively followed up non‐diabetic MASLD patients who used empagliflozin. Clinical, anthropometric, laboratory assessments and magnetic resonance imaging‐proton density fat fraction (MRI‐PDFF) were performed from baseline to week 52 (EOT). Baseline stool samples were collected, and shotgun DNA metagenomic sequencing was performed to profile microbiome. The primary outcome was treatment response to empagliflozin at EOT, defined as MRI‐PDFF decline ≥ 30% at EOT from baseline. Linear discriminant analysis [LDA] effect size was used to identify putative bacterial species. Multivariable logistic regression was used to derive adjusted odds ratio (aOR) of outcome with bacterial species by adjusting for clinical factors.

Results

Twenty‐two (48.9%) of 45 patients (median age: 56.9 years [IQR: 51.0–63.2]; male: 23 [51.1%]) achieved treatment response at EOT. There was difference in alpha diversity (Shannon index: p < 0.001; Simpson index: p = 0.001) and beta diversity ( p = 0.048) in baseline microbiome between treatment response and non‐response groups. Faecalibacterium prausnitzii (log 10 LDAscore = 4.27), Lachnospira pectinoschiza (log 10 LDAscore = 3.99), Anaerostipes hadrus (log 10 LDAscore = 3.98), Roseburia faecis (log 10 LDAscore = 3.97), Roseburia inulinivorans (log 10 LDAscore = 3.58) and Agathobaculum butyriciproducens (log 10 LDAscore = 2.77) were enriched in the treatment response group. L. pectinoschiza (aOR: 34.1; p = 0.015), A. hadrus (aOR:35.0; p = 0.032) and A. butyriciproducens (aOR:22.3; p = 0.023) independently predicted treatment response but not clinical factors. These three species collectively predicted treatment response with AUROC of 0.89 (95% CI: 0.80–0.99).

Conclusions

Certain gut bacterial species, particularly the combination of A. hadrus , L. pectinoschiza and A. butyriciproducens, may predict treatment response to empagliflozin in MAFLD patients without DM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal MicrobiomeGlucosidesBenzhydryl CompoundsSodium-Glucose Transporter 2 InhibitorsNon-alcoholic Fatty Liver DiseaseHumansMaleMiddle AgedFemaleProspective StudiesFecesTreatment OutcomeMagnetic Resonance ImagingLogistic ModelsAged

Stichwörter der Autor:innen

MAFLDMASHMASLDNAFLDNASHSGLT2 inhibitorsgut microbiota

Substanzen

GlucosidesBenzhydryl CompoundsempagliflozinSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong.
  • Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong.
  • State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong.

ORCID-Profile: Man Fung Yuen, Wai Kay Seto, Ka Shing Cheung

Förderung

  • General Research Fund, Research Grant Council, The Government of the Hong Kong Special Administrative Region

Zitieren

APA

Ng, H. Y., Zhang, L., Tan, J. T., Hui, R. W. H., Yuen, M. F., Seto, W. K., Leung, W. K., & Cheung, K. S. (2025). Gut Microbiota Predicts Treatment Response to Empagliflozin Among MASLD Patients Without Diabetes Mellitus. Liver International. https://doi.org/10.1111/liv.70023

Vancouver

Ng HY, Zhang L, Tan JT, Hui RWH, Yuen MF, Seto WK, et al. Gut Microbiota Predicts Treatment Response to Empagliflozin Among MASLD Patients Without Diabetes Mellitus. Liver International. 2025. doi:10.1111/liv.70023

BibTeX
@article{Ng2025,
  author = {Ng, Ho Yu and Zhang, Lina and Tan, Jing Tong and Hui, Rex Wan Hin and Yuen, Man Fung and Seto, Wai Kay and Leung, Wai K and Cheung, Ka Shing},
  title = {Gut Microbiota Predicts Treatment Response to Empagliflozin Among MASLD Patients Without Diabetes Mellitus},
  journal = {Liver International},
  year = {2025},
  doi = {10.1111/liv.70023}
}
Kostenlos starten →